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Background: Hydroxyapatite (HA) coatings composed with bisphosphonates (BPs) which have high mineral-
binding affinities have been confirmed to successfully enhance implant stability. However, few previous studies
focused on HA coatings composed with low-affinity BPs or on systemic effects of locally released BPs.
Methods: In this long-term study, we developed two kinds of BP-HA composite coatings using either high-affinity
BP (alendronate, ALN) or low-affinity BP (risedronate, RIS). Thirty-six rabbits were divided into three groups
according to different coating applications (group I: HA, group II: ALN-HA, and group III: RIS-HA). Implants were
inserted into the proximal region of the medullary cavity of the left tibiay. At insertion, 2 × 108 wear particles were
injected around implants to induce a peri-implant high bone turnover environment. Both local (left tibias) and
systemic (right tibias and lumbar vertebrae) inhibitory effect on bone resorption were compared, including
bone-implant integration, bone architecture, bone mineral density (BMD), implant stability, and serum levels of
bone turnover markers.
Results: The results indicated that ALN-HA composite coating, which could induce higher bone-implant contact
(BIC) ratio, bone mass augmentation, BMD, and implant stability in the peri-implant region, was more potent on
peri-implant bone, while RIS-HA composite coating, which had significant systemic effect, was more potent on
non-peri-implant bone, especially lumbar vertebrae.
Conclusions: It is instructive and meaningful to further clinical studies that we could choose different BP-HA
composite coatings according to the patient’s condition.Background
As the most effective surgical procedure for treating se-
vere arthritis and other joint-related diseases, the num-
ber of total joint arthroplasty (TJA) increases steadily
every year. Thus wear debris-induced aseptic loosening
and subsequent revision surgery may be unavoidable, es-
pecially for young patients.
Considerable studies have focused on preventing aseptic
loosening and enhancing implant stability in revision* Correspondence: xijingbone@yahoo.com.cn; xijingbone@yahoo.com.cn
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reproduction in any medium, provided the orsurgeries. BPs are a promising class of widely used drugs for
implant stability due to their inhibitory effects on osteoclasts
[1-6].
BPs have a P-C-P structure and two side-chains (R1 and
R2). Their mineral-binding affinities are mainly influenced by
R1 side-chain. In addition, R2 side-chain, three-dimensional
(3D) conformation, and the orientation of the nitrogen also
play a role [3]. Nancollas et al. [7] established a rank order of
their mineral- binding affinities: zoledronate (ZOL)>ALN>
ibandronate>RIS> etidronate> clodronate. The anti-re-
sorptive potency is mainly influenced by R2 side-chain, and
the rank order is: ZOL>RIS> ibandronate>ALN> pami-
dronate, which closely matches the order of potency on inhi-
biting farnesyl pyrophosphate synthase (FPPS) [3,8-10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tencies, systemically administrated high-affinity BPs
(ALN and ZOL) are effective on vertebral fractures,
while low-affinity BPs (RIS) are effective on all fracture
types, especially non-vertebral fractures [3,11]. The posi-
tive effects of BPs on bone-implant integration have
been widely studied by being administrated either sys-
temically (oral, intravenous or subcutaneous) [12-15] or
locally (peri-implant injection or composite coating de-
livery) [1,2,4,5,16-22].
Peri-prosthetic high bone turnover is the major patho-
logical response to aseptic loosening, so local BPs
treatment may be preferable for local high bone
turnover-related diseases. Digestive ulcer [23] and
osteonecrosis of the jaw [24] are the major side effects
caused by BPs treatment. High oral or intravenous dose
is considered to be the major cause of these side effects.
Because of the mineral-binding selectivity [25] and poor
oral bioavailability [8] of BPs, most BPs will be con-
sumed by non-peri-implant bone which has the highest
turnover rate [25], and be excreted via urine [8]. Thus,
patients have to take more BPs than their bone really
need if they take BPs systemically. Oppositely, if BPs are
administrated locally, the unnecessary consumption can
be avoided, and we do not need to worry about their
poor oral bioavailability. Therefore, lower drug dose than
systemic treatment will be enough, and dose-depended
side effects may be avoided. However, some problems
should be avoided if BPs are administrated locally that
local high drug concentration and massive bone compac-
tion may impair bone-implant integration [26,27].
Recently, some studies focused on the BP-HA com-
posite coatings to prevent aseptic loosening. Suratwala
et al. [4] developed a ZOL-HA composite coating, which
enhanced the peri-implant bone quality and implant sta-
bility in rats with aseptic loosening. However, as we
know, revision patients are averagely older than the pri-
mary patients that they have higher incidence rate of
systemic osteopenia or osteoporosis. Therefore, in
addition to enhancing implant stability, it is better for
the composite coatings to have systemic effects of bone
mass augmentation and BMD increment which may
benefit the recovery for revision patients. However, none
of previous studies investigated or compared the sys-
temic effects of locally released high-/low-affinity BPs.
In this long-term study, we developed two kinds of
BP-HA composite coatings using either high-affinity BP
(ALN) or low-affinity BP (RIS) in rabbits with peri-
implant high bone turnover rate. Both local and systemic
inhibitory effects on bone resorption were compared.
We hypothesised that the ALN-HA composite coating is
more effective on peri-implant bone while RIS-HA com-
posite coating has more obvious systemic effects and is
more effective on non-peri-implant bone.Methods
Experimental design
Thirty-six male New Zealand white rabbits
(3.00 ± 0.20 kg) were divided into three groups. The im-
plant was inserted into the proximal region of the me-
dullary cavity of the left tibia, and particles were injected
around the implant to induce a peri-implant high bone
turnover environment. In group I (n = 12), HA-coated
implants were not composed with BPs. In group II
(n = 12), HA-coated implants were composed with ALN.
In group III (n = 12), HA-coated implants were com-
posed with RIS. The study lasted for 24 weeks, and every
12 weeks six animals from each group were killed.
Particles and implants
Commercial pure ultra-high molecular weight polyethyl-
ene (UHMWPE) particles (average 1.74 ± 1.43 μm, range
0.05-11.06 μm) were obtained from the manufacturer
(Ceridust VP 3610, Clariant, Germany). Detailed para-
meters have been described by von Knoch et al. [28]. Be-
fore injection, the particles were tested using a
quantitative limulus amebocyte lysate assay to assure
that the endotoxin level was lower than 0.25 EU/mL.
Titanium alloy rods (Ti6Al4V, 2.5-mm diameter and
45-mm length) were plasma spray coated with HA (coat-
ing thickness = 30 μm, Ca/P = 1.67, Biomaterial Centre of
Sichuan University, Sichuan, China).
To prepare the BP-HA composite coatings, 100-μg of
ALN or 50-μg of RIS (potency is equivalent to 100-μg of
ALN) was dissolved in 100-μL of distilled water at 60 °C.
The solution was evenly dropped onto the surface of an
HA coating using a micropipette, and the coating was
entirely covered by the solution. Because 100-μL of solu-
tion could not be absorbed by the HA coating at once
(see Additional file 1), we rotated the implant (90
degrees) every 5 minutes until there was no dripping on
the implant, and then the implant was dried at 50 °C for
24 h and sterilised with gamma irradiation. Therefore,
the homogenous distribution of the BP solution on the
implant surface could be guaranteed.
The doses were referred to previous studies done by
other authors [15] and us (in press). Under these low
initial doses, peri-implant drug concentration could keep
at a low level for a long period that locally released BPs
could inhibit osteoclast activity without inhibiting osteo-
blast activity [4-6]. 100-μg/50-μg of locally administrated
ALN/RIS in a rabbit equates approximately to 50-mg/
25-mg of orally administrated ALN/RIS in an adult,
which are lower than their weekly doses.
Animals and surgery
Animals were anaesthetised with an intramuscular injec-
tion of ketamine (35 mg/kg) and xylazine (5 mg/kg).
After an incision was made to the left knee joint, a 2.5-
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plateau into the medullary cavity. Then 2 × 108
UHMWPE particles (suspended in 200-μL of saline)
were injected around implants to induce a high bone
turnover environment. Buprenorphine (0.04 mg/kg) was
administered subcutaneously every 6–12 h for two days
after surgery for postoperative pain control. Unrestricted
activity was allowed after surgery. Antibiotics were
administered 1 day preoperatively and 3 days postopera-
tively. On days 14 and 4 before being killed, the animals
received tetracycline (25 mg/kg) injections to label the
newly formed bone.
After sacrifice, bilateral tibias and lumbar vertebrae
(L2 and L3) were retrieved and fixed in 70% ethanol for
7 days. After fixation of the tibias, serial cross-sections
(Figure 1) were cut using a low speed saw (IsoMet,
Buehler LTD, Lake Bluff, IL). An 8-mm-thick cross-
section (section A) was cut 5-mm below the proximal
epiphyseal growth plate for dynamic histomorphometric
evaluation, and a 7-mm-thick cross-section (section B)
was cut for micro-CT scanning and push-out test. The
protocol was approved by our Institutional Animal Care
and Use Committee.Histomorphometry
Dynamic bone histomorphometry. Section A of bilateral
tibias (Figure 1) and the L2 vertebrae were embedded in
methylmethacrylate and two serial 15-μm thick slices of
each section were made using a hard tissue microtome
(Leica SP1600, Leica, Nussloch, Germany). They were
processed for toluidine blue staining and fluorescence
microscopy. The parameters were expressed in accord-
ance with the American Society of Bone and Mineral
Research (ASBMR) nomenclature, viz., bone formation
rate (BFR/BV) and mineral apposition rate (MAR).
Static bone histomorphometry. The BIC was defined
as the ratio of the implant surface covered with bone,Figure 1 A radiograph of bilateral tibias (group I) retrieved at
week 12 postoperatively. Levels (A and B) of the consecutive
cross-section specimens.and it was measured using toluidine blue-stained slices.
Section B of bilateral tibias (Figure 1) and the L3 verte-
brae were scanned using an eXplore Locus SP micro-CT
system (GE Healthcare, Healthcare, Milwaukee, WI).
The scanning protocol was set at 80 kV and 80 μA with
an exposure time of 3000 ms and the resolution of
21 × 21 × 21 μm. The scanning protocol was referred to
previous studies [19,20], the manual instruction of the
micro-CT system, and our previous study (in press). This
protocol can minimise the influence of scanning artifacts
induced by metal implants. The image data were ana-
lysed using GEHC MicroView software to measure
BMD and static bone histomorphometric parameters,
viz., bone volume fraction (BV/TV), trabecular thickness
(Tb.Th), trabecular separation (Tb.Sp), and structure
model index (SMI). Micro-CT was used to measure the
static histomorphometric parameters because it is based
on 3D imaging, which can reduce measurement errors.
Push-out test
Following micro-CT scanning, the biomechanical prop-
erties of section B of the left tibias were analysed using
an Autograph AGS-J (SHIMADZU, Japan) universal test
machine. The whole specimen was placed vertically on a
metal jig with a central opening, and the implant was
pushed out of the bone. A preload of 2 N defined the
start of the test, and the pushing speed was 0.5 mm/min.
During the pushing period, load–displacement curves
were generated. The detailed protocol was implemented
according to the studies by Dhert et al. [29] and Jakob-
sen et al. [16]. The maximum force (MF) was defined as
the peak value of the load–displacement curve, and ap-
parent shear stiffness (ASS) and total energy absorption
(TEA) were defined as the slope of the linear section of
the curve and the area under the curve until failure,
respectively.
Bone turnover markers
Serum levels of B-ALP (ADL, USA), TRACP-5b (SBA
Sciences, Finland), OPG and RANKL (R&D systems,
USA) were measured with enzyme-linked immunosorb-
ent assay (ELISA) kits according to the manufacturers'
instructions at weeks 12 and 24 post-operatively. The
intra- and inter-assay CVs for each assay were lower
than 7.6% and 5.3% (B-ALP), 8.0% and 6.5% (TRACP-
5b), and 6.7% and 5.5% (OPG and RANKL), respectively.
All the samples were tested in duplicate.
Statistical analysis
One-way ANOVA and Student-Newman-Keuls (SNK-q)
tests were performed for multiple comparisons among
all groups. A p value less than 0.05 was considered sig-
nificant, and data were expressed as means ± standard
deviations (SDs).
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No complications occurred during the experimental
period.
Bone-implant contact
As shown in Figure 2, both ALN- and RIS-HA compos-
ite coatings could increase BIC ratios significantly at
each time point (p< 0.05). At week 24, ALN (BIC =
51.82 ± 7.09%) showed stronger osteo-integrating effect
compared to RIS (BIC = 41.46 ± 9.15%, p< 0.05).
Bone histomorphometry
Dynamic bone histomorphometry. As shown in Figure 3,
both ALN and RIS reduced peri-implant (left tibia) BFR/
BV (−32% and −29%) and MAR (−28% and −24%) sig-
nificantly at week 12. However, only ALN reduced peri-
implant BFR/BV (−21%) and MAR (−22%) significantly
at week 24 (p< 0.05). Although RIS treatment resulted
in the lowest BFR/BV and MAR in right tibias, it showed
no significant differences between three groups. Only
RIS reduced BFR/BV (−18% at week 12 and −20% at
week 24) and MAR (−15% at week 12 and −17% at week
24) significantly in lumbar vertebrae (p< 0.05).
Static bone histomorphometry. As shown in Figure 3,
both ALN and RIS treatment resulted in significantly
higher peri-implant BV/TV (+112% and +99% at week
12, +199% and +133% at week 24, respectively) and Tb.
Th (+53% and +50% at week 12, +76% and +67% at
week 24, respectively) and lower Tb.Sp (−31% and −25%
at week 12, -42% and −27% at week 24, respectively) and
SMI (−36% and −32% at week 12, -43% and −30% at
week 24, respectively) compared to the control group at
each time point (p< 0.05), and ALN was more effectiveFigure 2 Bone-implant contact curves. a: significant vs. group I, b:
significant vs. group II. Data were expressed as means ± SDs. BIC:
bone-implant contact.than RIS. However, ALN did not have significant effect
in right tibias. Compared to the other groups, RIS treat-
ment resulted in the highest BV/TV and Tb.Th and the
lowest Tb.Sp and SMI in right tibias and lumbar verte-
brae at each time point. However, the effect of RIS be-
came insignificant in right tibias at week 24.
Micro-CT scanning (Figure 4) showed obvious lumbar
vertebral bone mass augmentation in RIS-treated ani-
mals, and these trabecular bones tended to be plate-like
in structure. However, ALN did not have the equivalent
effect on lumbar vertebrae.
Bone mineral density
As shown in Figure 3, both ALN and RIS treatment
resulted in significant peri-implant BMD augmentation,
and ALN was more effective than RIS (+12% at week 12
and +24% at week 24, p< 0.05). Although RIS treatment
resulted in the highest BMD augmentation in right
tibias, the effect of neither ALN nor RIS was significant.
In lumbar vertebrae, only RIS treatment resulted in sig-
nificant higher BMD augmentation than the control
group (p< 0.05).
Implant stability
As shown in Figure 5, both ALN and RIS improved im-
plant stability significantly at each time point (p< 0.05).
It was more obvious in ALN-treated animals at week 24
that ALN treatment resulted in higher ASS (+19%) and
TEA (+13%) at week 24 compared to RIS treatment
(p< 0.05).
Bone turnover markers
As shown in Figure 6, serum levels of both B-ALP
(−36% at week 12 and −22% at week 24) and TRACP-5b
(−77% at week 12 and −45% at week 24) reduced signifi-
cantly in group III at each time point and it was more
obvious at week 12 than week 24. However, ALN could
only reduce TRACP-5b (−38%) significantly at week 12
(p< 0.05). Serum levels of OPG and RANKL showed no
significant differences between three groups except the
significantly reduced serum level of RANKL (−25%) by
RIS treatment at week 12.
Discussion
Locally released BP from either ALN- or RIS-HA com-
posite coating could induce peri-implant bone mass aug-
mentation, BMD increment, and the improvement of
bone architecture, which significantly improved the
bone-implant integration (BIC increment), at each time
point (Figures 2, 3 (left tibia) and 4).
Early bone-implant integration that can provide a
sealed interface is important to implant stability because
it can inhibit the migration of debris and cytokines
[13,30]. In addition, implant stability is also influenced
Figure 3 Histomorphometric parameters and bone mineral
density. a: significant vs. group I, b: significant vs. group II, c:
within-group significant vs. week 12. Data were expressed as
means ± SDs. BFR/BV: bone formation rate, MAR: mineral apposition
rate, BV/TV: bone volume fraction, Tb.Th: trabecular thickness, Tb.Sp:
trabecular separation, SMI: structure model index.
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promised trabecular bone will transmit a lesser load to
the cortical bone. Thus, stress will concentrate at the
bone-implant interface, which ultimately results in im-
plant loosening. Rod-like trabecular bone (SMI = 3) had
poorer biomechanical properties than plate-like trabecu-
lar bone (SMI = 0). After the particle stimulation, SMI of
the peri-implant bone was higher than 2.0 (Figure 3,
SMI, left tibia, group I). However, locally released BP
from BP-HA composite coatings significantly reduced
SMI to almost 1.5 (Figure 3, SMI, left tibia, groups II
and III) and led to higher implant stability, which was
confirmed by the results of push-out test (Figure 5).
It was obvious that ALN was more potent than RIS on
peri-implant bone due to their different mineral-binding
affinities [8], especially at week 24. ALN has high
mineral-binding affinity and intermediate inhibitory po-
tency on FPPS. It can keep a stable concentration in
peri-implant bone and will hardly be delivered far away.
Therefore, previous studies [1,2,4,12-20,31,32] on enhan-
cing bone-implant integration almost focused on such
high-affinity BPs. Oppositely, RIS has low mineral-
binding affinity and high inhibitory effect on FPPS [7].
Such low-affinity BPs will be delivered to the entire
osteocyte network through the canalicular compartment
by extracellular fluid [3] that effective peri-implant drug
concentration may not be sustained for a long lime.
Therefore it is used for treating non-vertebral fractures
but not for enhancing bone-implant integration [3,11].Figure 4 Bone architecture of L3 vertebrae reconstructed by
micro-CT at weeks 12 and 24 postoperatively. RIS could induce
higher lumbar vertebral bone mass augmentation compared to ALN.
Figure 5 Push-out test. a: significant vs. group I, b: significant vs.
group II. Data were expressed as means ± SDs. MF: maximum force,
ASS: apparent shear stiffness, TEA: total energy absorption.
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older than the primary patients that they have a higher
incidence rate of systemic osteopenia or osteoporosis.
Therefore, in addition to enhancing implant stability, it
is better for the composite coatings to have systemic
effects of bone mass augmentation and BMD increment
which may benefit the recovery of revision patients.
However, the HA coating composed with high-affinity
BPs may not fit the needs as Jakobsen et al. [16] con-
firmed that locally released ALN did not have systemic
effects. Thus, we should re-consider the possibility of
using low-affinity BPs as coating materials.
The histomorphometric and BMD results of the
contralateral tibias and lumbar vertebrae (Figure 3) indi-
cated that RIS-HA composite coating could induce bone
mass augmentation and BMD increment significantly in
non-peri-implant region, especially lumbar vertebrae.Figure 6 The level of bone turnover makers measured by
ELISA. a: significant vs. group I, b: significant vs. group II. Data were
expressed as means ± SDs.Oppositely, ALN had very limited systemic effects. This
difference suggests that low-affinity BPs are more sys-
temically effective than high-affinity BPs. Additionally,
the variations of serum cytokine levels can reflect their
systemic effects more directly and precisely compared to
histomorphometric parameters. The significant lower
serum concentrations of B-ALP, TRACP-5b and RANKL
in group III than in groups I and II at week 12 also sup-
ported our histomorphometric results (Figure 6). The
effects of RIS were more pronounced in lumbar verte-
brae than contralateral tibias (Figure 3), because BPs
tend to bind with the bone which has the highest turn-
over rate [25]. Kimmel et al. [33] confirmed that lumbar
vertebrae and proximal humerus have the highest turn-
over rates.
Local BP administration (BP-HA composite coating) is
the best way for enhancing implant stability and pre-
venting aseptic loosening. Because of the binding select-
ivity of BPs, they will almost concentrate in the bone
with the highest turnover rate, such as the lumbar verte-
brae, but not in the peri-implant bone if they are admi-
nistrated systemically. The drug potency is then
diminished. Especially in the osteoporosis patients who
are usually in the state of systemic high bone turnover,
BP is more likely to be consumed by non-peri-implant
bone. Additionally, local administration has many advan-
tages such as lower initial dosage, higher peri-implant
drug concentration and fewer side effects compared to
systemic administration.
For inhibiting peri-implant bone resorption, low-
affinity BPs have some limitations that peri-implant drug
concentration may not sustain for a long time and their
effects on peri-implant bone will become weaker than
high-affinity BPs. In our study, it is obvious that BIC,
BV/TV, Tb.Sp, SMI, ASS, and TEA in group III became
significantly worse than in group II at week 24, and
BFR/BV and MAR showed no significant differences
compared to the control group (Figures 2, 3 (left tibia)
and 5). Therefore, low-affinity BP alone is not suitable
for revision patients who suffer from osteoporosis simul-
taneously. Composing HA with both high- and low-
affinity BPs may be feasible. Recently, Abtahi et al. [21]
composed both high- (pamidronate) and low-affinity
(ibandronate) BPs to the fibrinogen matrix as the coating
material, and each oral implant was then screwed into
the upper jaw in five patients. The results indicated that
this composite coating could successfully improve im-
plant stability. However, they did not explain why they
composed two kinds of BPs, and they did not compare it
with single BP composed coatings.
The mechanism by which BPs released from either
pure HA in vitro or bone in vivo are crucial to further
studies on composite HA coatings. In addition to differ-
ent mineral-binding affinities, the release duration of BPs
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will be consumed more rapidly in the sites with high
turnover rates. Thus, for further evaluating peri-implant
concentration and the release duration of BP-HA com-
posite coatings, detecting drug concentration in plasma
or bone is meaningful. Tanzer et al. [1] used a spectro-
photometric method [1,34] to investigate the in vitro re-
lease characteristic of ZOL from pure HA but it cannot
precisely reflect the release duration in vivo, because in
addition to chemical desorption, osteoclastic resorption
also plays an important role. Legay et al. [35] developed a
highly sensitive radioimmunoassay (RIA) method to de-
tect ZOL concentration, and the limit of quantification
was 0.4 ng/mL in plasma and 5 ng/mL in urine, respect-
ively. Yun et al. [36] developed a high-performance li-
quid chromatography (HPLC) method to detect ALN
concentration, and the limit of quantification was 1 ng/
mL in plasma. These methods are not sensitive enough
for our study because the doses of ALN and RIS were
100-μg and 50-μg, respectively, per implant, that the
drug concentration was too low to detect, especially in
plasma. Recently, Stadelmann et al. [22] developed a
novel mathematic-based modelling method for evaluat-
ing peri-implant BP concentration and bone density.
Using this method, they found the optimal coating dose
of ZOL per implant. All these efforts mentioned above
will help us further realise the characteristic of BP-HA
composite coatings.
The results of this study are instructive and meaning-
ful to further clinical studies that we could choose differ-
ent BP-HA composite coatings according to the patient’s
condition. In brief: 1) In primary TJA patients without
systemic high bone turnover-related diseases (osteopenia
or osteoporosis), we can prefer ordinary non-BP-
composed prostheses; 2) In primary TJA patients with
systemic high bone turnover-related diseases, we can
prefer low-affinity BP-composed prostheses. Their sig-
nificant systemic effects may cooperate with the BP
which is systemically administrated. The systemic bone
mass augmentation and BMD increment can result in
earlier movement and shorter recovery time for patients;
3) In revision patients without systemic high bone
turnover-related diseases, we can prefer high-affinity BP-
composed prostheses which can significantly reduce
peri-implant high bone turnover rate and improve im-
plant stability due to the stable peri-implant drug con-
centration and long release duration; 4) In revision
patients with systemic high bone turnover-related dis-
eases, the HA coating composed with both high- and
low-affinity BPs may be preferable, in addition to im-
proving implant stability, it can result in systemic bone
mass augmentation and BMD increment.
Nevertheless, our study has some limitations. Firstly,
the homogenous distribution of the BP solution on theimplant surface could be guaranteed due to the implant
size and the BP solution volume in our study. However,
in further studies, if the implant is bigger or the solution
amount is less, the homogenous distribution may not be
guaranteed. Therefore, other loading methods like spray-
ing may be possible if the drug amount can be con-
trolled at the same time. Secondly, we compared local
and systemic inhibitory effects on bone resorption only
between high- and low-affinity BPs. In further studies,
an additional group that the HA coating is composed
with both high- and low-affinity BPs should be added
and an appropriate ratio of high-/low-affinity BPs should
be investigated. Finally, the animal model used in this
study was to induce peri-implant (local) high bone turn-
over. In further studies, these composite coatings should
be studied in osteoporosis models which have systemic
high bone turnover rate.
Conclusions
In this long-term study, we developed two kinds of BP-
HA composite coatings using either high- or low-affinity
BPs in rabbits. The results indicated that ALN-HA com-
posite coating was more effective on peri-implant bone,
while RIS-HA composite coating was more effective on
non-peri-implant bone, especially lumbar vertebrae. It is
instructive and meaningful to further clinical studies that
we could choose different BP-HA composite coatings
according to the patient’s condition.Additional file
Additional file 1: BP-HA composite coating. The top figure shows the
HA-coated implant which has not been loaded, and we can see the HA
coating is dry. After loading with 100-μL of BP solution, as shown in the
bottom figure, the implant surface is entirely covered with the solution.
We rotated the implants (90 degrees) every 5 minutes until there was no
dripping (arrow) on the implant surface.
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